← Back to Search

Alkylating agents

Gemcitabine + Cisplatin for Bladder Cancer

Phase 2
Recruiting
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No pre-existing sensory grade >= 2 neuropathy
No known HIV or AIDS-related illness or other active infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Study Summary

This trial studies gemcitabine hydrochloride and cisplatin as a treatment for bladder cancer.

Who is the study for?
This trial is for adults with muscle-invasive bladder urothelial cancer who are suitable for radical cystectomy, have not had systemic chemotherapy in the past 5 years, and no prior anti-PD-1 or anti PD-L1 therapies. They should not be pregnant or nursing, must have good organ function and performance status (able to carry out daily activities), and cannot have a history of certain heart conditions or other serious illnesses.Check my eligibility
What is being tested?
The trial tests how well gemcitabine hydrochloride and cisplatin treat invasive bladder urothelial cancer without surgery. It's a phase II study where these chemotherapy drugs aim to stop tumor growth by killing cells or preventing them from dividing/spreading.See study design
What are the potential side effects?
Possible side effects include nausea, vomiting, hair loss, low blood cell counts leading to increased infection risk and bleeding problems, kidney damage, nerve damage that can cause numbness or pain in hands/feet (neuropathy), hearing loss, and allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have significant numbness or tingling in my hands or feet.
Select...
I do not have HIV, AIDS, or any other active infection.
Select...
I am fully active or can carry out light work.
Select...
I do not have any serious ongoing health or mental health conditions.
Select...
My cancer is at a stage where it has grown but not spread to distant parts.
Select...
I can provide 20 slides of my cancer tissue from before treatment for testing.
Select...
My cancer has not spread beyond its original location.
Select...
I do not have multiple areas of early-stage cancer; only one area is present.
Select...
My bladder tumor is no larger than 5 cm, as confirmed by a bladder examination.
Select...
I haven't had PD-1/PD-L1 inhibitors or chemotherapy in the last 5 years.
Select...
I have not had radiation therapy to my bladder or prostate.
Select...
My bladder cancer has been confirmed by a biopsy.
Select...
My heart condition does not severely limit my daily activities.
Select...
I do not have serious heart rhythm problems.
Select...
I've finished 4+ cycles of chemotherapy and have my DDR gene results.
Select...
My bladder cancer has a specific genetic change.
Select...
My kidneys are functioning well.
Select...
I haven't had a heart attack, stroke, or major heart surgery in the last 6 months.
Select...
I do not have significant hearing loss.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients who are recurrence-free within the DDR mutated group who undergo the bladder sparing approach
Secondary outcome measures
Bladder-intact survival in DDR-altered patients with < cT1 responses who selected the bladder sparing approach
Clinical response rate for patients harboring deleterious DDR gene alterations
Overall survival
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)Experimental Treatment5 Interventions
Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
Group II: Arm I (gemcitabine, cisplatin, bladder sparing)Experimental Treatment4 Interventions
Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pegfilgrastim
2013
Completed Phase 3
~4410
Conventional Surgery
2006
Completed Phase 3
~1080
Cisplatin
2013
Completed Phase 3
~1940
Gemcitabine Hydrochloride
2005
Completed Phase 3
~5420
Radical Cystectomy
2006
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Alliance for Clinical Trials in OncologyLead Sponsor
512 Previous Clinical Trials
217,363 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,587 Previous Clinical Trials
41,242,231 Total Patients Enrolled
Gopa Iyer, MDStudy ChairMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
75 Total Patients Enrolled

Media Library

Cisplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT03609216 — Phase 2
Bladder Cancer Research Study Groups: Arm I (gemcitabine, cisplatin, bladder sparing), Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)
Bladder Cancer Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT03609216 — Phase 2
Cisplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03609216 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How perilous is Radical Cystectomy for those who undergo the procedure?

"Based on the limited evidence of safety, Radical Cystectomy was awarded a score of 2. However, there is not yet any clinical data that confirms its efficacy."

Answered by AI

In what contexts is Radical Cystectomy typically recommended?

"Radical Cystectomy is often employed to treat neoplasm metastasis, as well as certain infections and advanced stages of testicular cancer. Additionally, it has been used to address urinary bladder issues."

Answered by AI

How many participants are currently engaged in this clinical trial?

"In order to conduct this research, 271 patients meeting the pre-established requirements must sign up. Potential participants can visit The Melanoma and Skin cancer Institute in Englewood or the Cancer Care Center of O'Fallon in Illinois for enrolment."

Answered by AI

At what specific sites is this investigation taking place?

"This investigation is taking place in 3 primary sites: The Melanoma and Skin cancer Institute of Englewood, Colorado; the Cancer Care Center of O'Fallon, Illinois; and IHA Hematology Oncology Consultants-Canton in Michigan. Additionally, it is recruiting from a further 100 clinical centres."

Answered by AI

Are there still vacancies in the trial for participants?

"Data hosted on clinicaltrials.gov demonstrates that this medical study, which was initially published on August 1st 2018, is actively recruiting participants. Most recently the details were updated at September 25th 2022."

Answered by AI

What other experiments have been performed concerning Radical Cystectomy?

"Since 1997, the City of Hope Comprehensive Cancer Center has been researching Radical Cystectomy. To date, 1763 studies have concluded and 1001 are currently recruiting participants; many in Englewood, Colorado."

Answered by AI
~93 spots leftby Feb 2027